Front Row Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$978 Hold
18
﹤0.01% 528
2025
Q4
$1.01K Hold
18
﹤0.01% 509
2025
Q3
$867 Sell
18
-9
-33% -$402 ﹤0.01% 511
2025
Q2
$1.1K Sell
27
-18
-40% -$724 ﹤0.01% 494
2025
Q1
$1.98K Hold
45
﹤0.01% 448
2024
Q4
$1.94K Hold
45
﹤0.01% 445
2024
Q3
$2K Hold
45
﹤0.01% 445
2024
Q2
$1.8K Hold
45
﹤0.01% 859
2024
Q1
$1.95K Hold
45
﹤0.01% 848
2023
Q4
$1.88K Hold
45
﹤0.01% 417
2023
Q3
$1.8K Hold
45
﹤0.01% 822
2023
Q2
$2K Hold
45
﹤0.01% 831
2023
Q1
$2K Buy
+45
New +$1.89K ﹤0.01% 846
2022
Q4
Sell
-45
Closed -$1.87K 950
2022
Q3
$2K Hold
45
﹤0.01% 844
2022
Q2
$2K Hold
45
﹤0.01% 854
2022
Q1
$2K Buy
45
+1
+2% +$44 ﹤0.01% 883
2021
Q4
$2K Hold
44
﹤0.01% 897
2021
Q3
$2K Hold
44
﹤0.01% 891
2021
Q2
$2K Hold
44
﹤0.01% 894
2021
Q1
$2K Hold
44
﹤0.01% 889
2020
Q4
$2K Hold
44
﹤0.01% 851
2020
Q3
$2K Hold
44
﹤0.01% 849
2020
Q2
$2K Hold
44
﹤0.01% 886
2020
Q1
$2K Hold
44
﹤0.01% 860
2019
Q4
$2K Hold
44
﹤0.01% 819
2019
Q3
$2K Hold
44
﹤0.01% 823
2019
Q2
$2K Hold
44
﹤0.01% 884
2019
Q1
$2K Buy
+44
New +$1.79K ﹤0.01% 882

Other funds holding XPH

Front Row Advisors's XPH Position: Q1 2026 in Review

Front Row Advisors held its State Street SPDR S&P Pharmaceuticals ETF (XPH) position steady in Q1 2026 at 18 shares worth $978. The position accounts for ﹤0.01% of the portfolio, ranked #528.

Front Row Advisors first reported a position in XPH in Q1 2019 and has held it in 28 quarters since. The position peaked at $2K in Q3 2024. 82 funds tracked by Wall St. Rank hold XPH as of Q1 2026.

  • Front Row Advisors held 18 shares of State Street SPDR S&P Pharmaceuticals ETF worth $978 as of Q1 2026.
  • Front Row Advisors left its State Street SPDR S&P Pharmaceuticals ETF share count unchanged in Q1 2026.
  • State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Front Row Advisors's portfolio in Q1 2026, its #528 holding.
  • Front Row Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2019 and has held it in 28 quarters since.
  • Front Row Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $2K in Q3 2024.
  • 82 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.